The group's principal activities are to discover, develop and commercialize small molecule therapeutics. The therapeutic drugs are used for the treatment of cancer, diabetes and inflammatory diseases. The group's development product includes tlk286, tlk199 and tlk19781. Tlk286, is a small molecule tumor-activated cancer drug that is resistant to standard chemotherapy drugs. Tlk199, is a small molecule bone marrow stimulant developed for the treatment of blood disorders associated with low white blood cell levels or neutropenia. Tlk19781 is a proprietary, orally active small molecule insulin receptor activator for the treatment of type 2 diabetes and other conditions related to insulin resistance.
